The development of acamprosate as a treatment against alcohol relapse

Peter R. Kufahl, Lucas R. Watterson, Michael Olive

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction: Globally, alcohol abuse and dependence are significant contributors to chronic disease and injury and are responsible for nearly 4% of all deaths annually. Acamprosate (Campral), one of only three pharmacological treatments approved for the treatment of alcohol dependence, has shown mixed efficacy in clinical trials in maintaining abstinence of detoxified alcoholics since studies began in the 1980s. Yielding inconsistent results, these studies have prompted skepticism.Areas covered: Herein, the authors review the preclinical studies which have assessed the efficacy of acamprosate in various animal models of alcohol dependence and discuss the disparate findings from the major clinical trials. Moreover, the authors discuss the major limitations of these preclinical and clinical studies and offer explanations for the often-contradictory findings. The article also looks at the importance of the calcium moiety that accompanies the salt form of acamprosate and its relevance to its activity.Expert opinion: The recent discovery that large doses of calcium largely duplicate the effects of acamprosate in animal models has introduced a serious challenge to the widely held functional association between this drug and the glutamate neurotransmission system. Future research on acamprosate or newer pharmacotherapeutics should consider assessing plasma and/or brain levels of calcium as a correlate or mediating factor in anti-relapse efficacy. Further, preclinical research on acamprosate has thus far lacked animal models of chemical dependence on alcohol, and the testing of rodents with histories of alcohol intoxication and withdrawal is suggested.

Original languageEnglish (US)
Pages (from-to)1355-1369
Number of pages15
JournalExpert Opinion on Drug Discovery
Volume9
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Alcohols
Alcoholism
Recurrence
Animal Models
Calcium
Therapeutics
Clinical Trials
Alcoholic Intoxication
Expert Testimony
Alcoholics
acamprosate
Synaptic Transmission
Glutamic Acid
Rodentia
Chronic Disease
Salts
Pharmacology
Wounds and Injuries
Brain
Research

Keywords

  • Acamprosate
  • Alcoholism
  • Calcium
  • Craving
  • Glutamate
  • Relapse

ASJC Scopus subject areas

  • Drug Discovery

Cite this

The development of acamprosate as a treatment against alcohol relapse. / Kufahl, Peter R.; Watterson, Lucas R.; Olive, Michael.

In: Expert Opinion on Drug Discovery, Vol. 9, No. 11, 01.11.2014, p. 1355-1369.

Research output: Contribution to journalArticle

Kufahl, Peter R. ; Watterson, Lucas R. ; Olive, Michael. / The development of acamprosate as a treatment against alcohol relapse. In: Expert Opinion on Drug Discovery. 2014 ; Vol. 9, No. 11. pp. 1355-1369.
@article{b19a360c9e4c4e698fe05afb07550afa,
title = "The development of acamprosate as a treatment against alcohol relapse",
abstract = "Introduction: Globally, alcohol abuse and dependence are significant contributors to chronic disease and injury and are responsible for nearly 4{\%} of all deaths annually. Acamprosate (Campral), one of only three pharmacological treatments approved for the treatment of alcohol dependence, has shown mixed efficacy in clinical trials in maintaining abstinence of detoxified alcoholics since studies began in the 1980s. Yielding inconsistent results, these studies have prompted skepticism.Areas covered: Herein, the authors review the preclinical studies which have assessed the efficacy of acamprosate in various animal models of alcohol dependence and discuss the disparate findings from the major clinical trials. Moreover, the authors discuss the major limitations of these preclinical and clinical studies and offer explanations for the often-contradictory findings. The article also looks at the importance of the calcium moiety that accompanies the salt form of acamprosate and its relevance to its activity.Expert opinion: The recent discovery that large doses of calcium largely duplicate the effects of acamprosate in animal models has introduced a serious challenge to the widely held functional association between this drug and the glutamate neurotransmission system. Future research on acamprosate or newer pharmacotherapeutics should consider assessing plasma and/or brain levels of calcium as a correlate or mediating factor in anti-relapse efficacy. Further, preclinical research on acamprosate has thus far lacked animal models of chemical dependence on alcohol, and the testing of rodents with histories of alcohol intoxication and withdrawal is suggested.",
keywords = "Acamprosate, Alcoholism, Calcium, Craving, Glutamate, Relapse",
author = "Kufahl, {Peter R.} and Watterson, {Lucas R.} and Michael Olive",
year = "2014",
month = "11",
day = "1",
doi = "10.1517/17460441.2014.960840",
language = "English (US)",
volume = "9",
pages = "1355--1369",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - The development of acamprosate as a treatment against alcohol relapse

AU - Kufahl, Peter R.

AU - Watterson, Lucas R.

AU - Olive, Michael

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Introduction: Globally, alcohol abuse and dependence are significant contributors to chronic disease and injury and are responsible for nearly 4% of all deaths annually. Acamprosate (Campral), one of only three pharmacological treatments approved for the treatment of alcohol dependence, has shown mixed efficacy in clinical trials in maintaining abstinence of detoxified alcoholics since studies began in the 1980s. Yielding inconsistent results, these studies have prompted skepticism.Areas covered: Herein, the authors review the preclinical studies which have assessed the efficacy of acamprosate in various animal models of alcohol dependence and discuss the disparate findings from the major clinical trials. Moreover, the authors discuss the major limitations of these preclinical and clinical studies and offer explanations for the often-contradictory findings. The article also looks at the importance of the calcium moiety that accompanies the salt form of acamprosate and its relevance to its activity.Expert opinion: The recent discovery that large doses of calcium largely duplicate the effects of acamprosate in animal models has introduced a serious challenge to the widely held functional association between this drug and the glutamate neurotransmission system. Future research on acamprosate or newer pharmacotherapeutics should consider assessing plasma and/or brain levels of calcium as a correlate or mediating factor in anti-relapse efficacy. Further, preclinical research on acamprosate has thus far lacked animal models of chemical dependence on alcohol, and the testing of rodents with histories of alcohol intoxication and withdrawal is suggested.

AB - Introduction: Globally, alcohol abuse and dependence are significant contributors to chronic disease and injury and are responsible for nearly 4% of all deaths annually. Acamprosate (Campral), one of only three pharmacological treatments approved for the treatment of alcohol dependence, has shown mixed efficacy in clinical trials in maintaining abstinence of detoxified alcoholics since studies began in the 1980s. Yielding inconsistent results, these studies have prompted skepticism.Areas covered: Herein, the authors review the preclinical studies which have assessed the efficacy of acamprosate in various animal models of alcohol dependence and discuss the disparate findings from the major clinical trials. Moreover, the authors discuss the major limitations of these preclinical and clinical studies and offer explanations for the often-contradictory findings. The article also looks at the importance of the calcium moiety that accompanies the salt form of acamprosate and its relevance to its activity.Expert opinion: The recent discovery that large doses of calcium largely duplicate the effects of acamprosate in animal models has introduced a serious challenge to the widely held functional association between this drug and the glutamate neurotransmission system. Future research on acamprosate or newer pharmacotherapeutics should consider assessing plasma and/or brain levels of calcium as a correlate or mediating factor in anti-relapse efficacy. Further, preclinical research on acamprosate has thus far lacked animal models of chemical dependence on alcohol, and the testing of rodents with histories of alcohol intoxication and withdrawal is suggested.

KW - Acamprosate

KW - Alcoholism

KW - Calcium

KW - Craving

KW - Glutamate

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84911497587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911497587&partnerID=8YFLogxK

U2 - 10.1517/17460441.2014.960840

DO - 10.1517/17460441.2014.960840

M3 - Article

C2 - 25258174

AN - SCOPUS:84911497587

VL - 9

SP - 1355

EP - 1369

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 11

ER -